Gold vs US Dollar

Register to chat with like-minded investors on our interactive forums.

Get Started

Home
Investing
Stocks
UK
LSE
Omega Diagnostics Group Plc (ODX)
Omega Diagnostics Group Plc (ODX) Share Price

ODX Omega Diagnostics Group Plc

2.20

0.00 (0.0%)

28 Nov 2023 - Closed

Delayed by 15 minutes

Share Name	Share Symbol	Market	Type	Share ISIN	Share Description
Omega Diagnostics Group Plc	LSE:ODX	London	Ordinary Share	GB00B1VCP282	ORD 4P

	Price Change	% Change	Share Price	Shares Traded	Last Trade
	0.00	0.0%	2.20	0.00	00:00:00

Bid Price		Offer Price	High Price	Low Price	Open Price
2.00		2.40

Industry Sector	Turnover	Profit	EPS - Basic	PE Ratio	Market Cap
				-

Last Trade Time	Trade Type	Trade Size	Trade Price	Currency
-	O	0	2.20	GBX

Related Shares
Smith & Nephew (SN.), Convatec (CTEC), Aptamer (APTA), Deepverge (DVRG)

Omega Diagnostics (ODX) Latest News (1)

Omega Diagnostics News

Date	Time	Source	Headline
28/11/2023	15:56	UKREG	Cambridge Nutritional Sciences PLC Holding(s) in Company
23/11/2023	07:00	UKREG	Cambridge Nutritional Sciences PLC Half-year Report
22/11/2023	10:59	UKREG	Cambridge Nutritional Sciences PLC Holding(s) in Company
20/11/2023	11:09	UKREG	Cambridge Nutritional Sciences PLC Holding(s) in Company
17/11/2023	12:55	UKREG	Cambridge Nutritional Sciences PLC Holding(s) in Company
10/11/2023	07:00	UKREG	Cambridge Nutritional Sciences PLC Warrant Expiry and Block Admission..
06/11/2023	07:00	UKREG	Cambridge Nutritional Sciences PLC Notice of Results and Investor..
27/10/2023	17:06	UKREG	Cambridge Nutritional Sciences PLC Holding(s) in Company
13/10/2023	12:12	UKREG	Cambridge Nutritional Sciences PLC Holding(s) in Company
02/10/2023	12:10	UKREG	Cambridge Nutritional Sciences PLC Holding(s) in Company

More Omega Diagnostics News

Omega Diagnostics Investors Omega Diagnostics Takeover Rumours

Omega Diagnostics (ODX) Discussions and Chat

Omega Diagnostics Forums and Chat

Date	Time	Title	Posts
23/11/2023	07:08	short of money	169
10/10/2023	18:59	Omega Diagnostics - nicely poised for significant growth	16,443
06/9/2023	06:47	Omega Diagnostics Group Plc	866
11/6/2023	20:50	Bullshit Free Zone	634
15/5/2023	20:43	CV and the Deep State	94

Add a New Thread

Omega Diagnostics (ODX) Most Recent Trades

No Trades

Trade Time	Trade Price	Trade Size	Trade Value	Trade Type

View all Omega Diagnostics trades in real-time

Omega Diagnostics (ODX) Top Chat Posts

Top Posts
Posted at 31/8/2023 11:53 by twatcher I bet the "safe haven for all reasonable ODX shareholders.", is really loving this, those reasonable ODX shareholders wouldn't possibly be critical...would they ? Read Full Thread Reply
Posted at 31/8/2023 06:39 by terminator101 No company that has ever done a share consolidation has done well for existing investors. "Provides more options for the company in the future" tells you everything you need to know ;-) Read Full Thread Reply
Posted at 14/8/2023 08:16 by terminator101 Finally they post their results. No wonder they wanted to try and stall. Revenue down. Losses up. But nice that Jay more than doubled his salary to £351,000 So don't worry as no director has suffered any hardship as a result of the "transformation" of the share price. Read Full Thread Reply
Posted at 25/7/2023 10:24 by hooded claw Oh dear, GDR rise was due to a field ODX have nothing to do with Read Full Thread Reply
Posted at 21/3/2023 07:01 by xtrmntr The cash flow statement is the first thing I go to when looking at the financial statements.We're going to do a walkthrough on a company that was popular last year called Omega Diagnostics (ODX).What went wrong?This is a company that got caught up in the testing hype, then failed to deliver on its revenues.Some blame the government. Some blame the board.But regardless of who is to blame, the warning signs were clear in the cash flow statement.Cash flow statements show how cash moves through the business and can tell us if a company:may need to raise moneyconverts its profits into cashis spending hefty amounts on capexBy the end of this email, you'll know how to work your way around the three parts of the cash flow statement.Let's get started on the first part: the cash flow statement of operations. Operating cash flow statement (OCF)The operating cash flow statement shows if a business is self-sustaining in its ordinary course of business.It starts with the company's bottom line (net income/loss) and then works its way back to cash generated/used from operations by the company.To do this, the company adjusts items on its P&L.Let's look at ODX's cash flow statement.Source: SharePad (risk-free trial and free month worth £74 here)This company made a £2.7m loss in its half-year report.But it doesn't mean that it used £2.7m from its cash reserves.This is where the OCF comes in handy.For example, we can see straight away that the company adjusts for depreciation.Depreciation is the writing down of a tangible asset across its useful life on the P&L.But depreciation doesn't affect the company's cash position - so it's added back.The same goes for amortisation.Amortisation is the testing of an intangible asset for impairment.It's also a non-cash expense.We also add back share-based payments.As an aside - some management teams will tell you that these aren't a real cost because they are non-cash.But share-based payments can make a huge difference to the P&L and ultimately your share of the profits as an owner of the business.Anyway, let's continue..Some companies will provide a number used in operations before the movements in working capital.But these movements can be significant. Now, if "Increase in trade and other receivables" grows, this means more people paid on credit burning the year.And if it's negative, this can mean one of two things:the company has been proactive at chasing up those who owe it moneythe business is slowing down hence why receivables haven't been growingA stretched receivables book can be poor for working capital purposes, so always check the cash position on the balance sheet.And if the number in "Increase and trade and other payables" is positive, then it means the company owes more money.A decrease means it has paid and capital has left the business.Companies that get paid quicker than they pay cash out see a higher cash balance within the business. This is generally what I like to see.In the case of ODX, we can see that it burned through £1.8m in six months. If we do a rough calculation and divide this up then we get an outflow of ~£300k per month.Investing cash flow statement (ICF)The second section of the cash flow statement is the cash flows from investing activities.This includes:capital expenditure (capex)acquisitions with own capitalcapital raised from selling investmentsThis section will often be negative. But that isn't necessarily a negative.Capex can be be either maintenance or expansionary.Maintenance capex is capital that the business needs to spend on to keep the company running.For example, companies with large fixed assets such as restaurants or machinery will need to spend to keep these assets in good working order.Expansionary capex is capital that the company is investing in to grow. This is more exciting for investors.You can also calculate Free Cash Flow (FCF) here.FCF is what is left after the business has made all of its commitments.FCF is calculated by taking the company's cash flows from operating activities and subtracting capex.FCF = OCF - CapexLet's look at ODX's investing cash flow statement.We can see that the company spent £673k on the purchase of property, plant, and equipment.We can also see that management spent £411k on the purchase of intangible assets.This doesn't tell us much, and we don't know what was bought and why.But we do know that nearly £1.1m of the company's cash balance was spent on investments during this period.Financing Cash Flow (FCF)The final part of the cash flow statement is the cash flow from financing activities.This part shows us how the company financed itself through the period.A big positive number here usually means that the company raised capital.Here's ODX's financing cash flow statement:We can see that the company only raised £57k from the proceeds of issuing share capital.But in the prior period we see a big number - Omega Diagnostics raised £11m from a share placing the year before - and spent £551k on broker fees to help it achieve this.We also see other costs and get a final number at the bottom. So what does this mean?We can see that cash declined to £4.7m from £5.8m. We also know this number got a £2m boost from a DHSC contribution (as listed in the FCF).And we also know that the co is burning through roughly £1.8m per month. It also spent £1m on investing.But here's the crucial part. This report is from 25 November 2021.The date it reports on was for the period ending 30 September 2021.So you have to start calculating the £300k per month cash burn from that period.In an RNS on 10 December 2021, the company announced that the Department of Health and Social Care had acknowledged that the contract had expired (meaning no further revenue).It also requested that the company should repay the previous contribution along with the VAT which is £2.5m.Omega also said that it had taken further legal advice (more capital burned).At this point, anyone who had read the cash flow statement would've known it was clear that the company was in trouble financially.Stage four stocksHowever, even if you didn't know what a cash flow statement was, ODX was clearly a stage four stock.Let's look at the chart.Source: SharePad (risk-free trial and 1 free month worth £74 here)The stock topped out around 130p.Since then, the stock fell through all of its moving averages (another warning sign), then all of the moving averages started pointing down (another warning sign).It doesn't matter how good a company looks - I'm not tough enough to fight the trend.The company even announced it was discussing an equity placing: "Market conditions remain challenging and accordingly any issue of equity would be at a discount to the current share price."Of course, this is easy for me to say in hindsight. But I've taken a big hit in the past myself because:1) I didn't understand cash flow statements2) I ignored a falling chart, and more importantly3) I was emotionally invested and buried my head in the sand.This last point is key.Once you feel any hint of emotion to a stock - you're at a disadvantage.Trading is a ruthless business.If you're not able to cut stocks without emotion - you will struggle. Read Full Thread Reply
Posted at 09/3/2023 12:46 by the technical trader A wise decision. From a technical perspective the upside looks phenomenal. The fundamentals back up the technicals too. Essentially ODX have put the Covid fiasco behind them and the business is focussing on its core product (nutrition). In fact, it was the only area of the business that was profitable (Jag's bit). They can't make these test quick enough, orders are increasing, and they're having to put back short term gain for more strategic benefit, and that's why they're investing in more production capacity. With the US markets exposure, we could see massive upside here. The near-term upside could even eclipse Covid testing highs, as these C19-LFT tests were always going to be a flash in the pan. Directors are putting their money on the line now too. I'm expecting a 10 fold increase by the end of the year. Read Full Thread Reply
Posted at 29/1/2023 13:41 by thirty fifty twenty hi misterx yes i agree completely. in particular i have researched the CFO's patterns and involvement with the other PLC's he has been involved with in the past and then too (twice) he has bought at prices before then selling the business to an outsider at much higher prices (12-18mths later). also they are both heavily incentivised with share options etc... so why spend real money when one is going to be rewarded anyway, unless it seems like an excellent risk/reward. the only negative scenario i could contemplate is that they are trying to inflate the price ... now they dont need to do that to raise funds (since they have c.5m net CASH in the bank) but it was for acquisitions? so i see that as a possibility (albeit outside) but one which i would be happy with as any acquisitions increase the size of the MV which brings in more investors which typically gives the overall company a higher rating. so, for me, all the scenerios seem positive. though the biggest sign overall is the fantastic chart which has obviously shaken the crash from the covid mania peaks and is now forming a very strong recovery pattern. All IMHO, DYOR + BoL ODX is in my top5 holdings Read Full Thread Reply
Posted at 25/11/2022 13:38 by smithie6 btw I think there is 1 mistake in your write up it mentions cash raise at 5p, whereas I think you meant "at 4p" ---- "On 6 May 2022, Omega announced its intention to raise gross proceeds of up to £4.1 million by way of a Placing, Subscription and Open Offer (together the "Fundraising"), all at an issue price of 4 pence per New Ordinary Share." ---- I think it would be useful, if you could consider to update your write up to make it clear what is the situation of the building that ODX plans to move to. For example - is it being built for ODX (I think yes, either built or modified) - does ODX have any TNAV in it or is it all going to be a leased building ? - ODX now don't plan to move until 2025 I think. Does ODX have to pay any rental/lease costs in '23 or '24 if the building is ready but ODX leaves it empty ?? I don't know. I think various ppl would like to know. Read Full Thread Reply
Posted at 31/3/2022 14:58 by hedgehog 100 What is a fair EV (enterprise value) valuation for ODX, before and after a bid. Well, IDH (Immunodiagnostic Systems Holdings) was taken over last May for c. £110M., an enterprise value of c. £88M. IDH's full year sales to 31.3.21 were £32.7M., and the H1 loss was about £3M. = An EV sales multiple of c. 2.7. Assuming full year ODX sales of say c. £12M., and applying a sales multiple of say c. 1.35, gives a value of c. £16M., or about 9p/share. I.e. well over double the current share price. And a bid could see that multiple moving much higher. That looks like a pretty good margin of safety to me, at the current share price of 3.85p. 17/05/2021 07:00 UK Regulatory (RNS & others) PerkinElmer Inc Offer for Immunodiagnostic Systems Holdings Plc LSE:IDH Immunodiagnostic Systems Holdings Plc " ...The boards of PerkinElmer, Inc. ("PerkinElmer") and Immunodiagnostic Systems Holdings PLC ("IDS") are pleased to announce that they have reached agreement on the terms of a recommended all cash offer whereby the entire issued and to be issued ordinary share capital of IDS will be acquired by PerkinElmer (UK) Holdings Limited ("PerkinElmer UK") (the "Acquisition"). -- Under the terms of the Acquisition, each IDS Shareholder will be entitled to receive: 382 pence in cash per IDS Share -- The Acquisition values the entire issued and to be issued ordinary share capital of IDS at approximately GBP110 million ($155 million), on the basis of a fully diluted share capital of 28,865,469 IDS Shares. This implies an enterprise value of IDS of approximately GBP88 million ($124 million). -- The price of 382 pence in cash per IDS Share represents a premium of approximately: -- 49.8 per cent. to the Closing Price of 255 pence per IDS Share on the Last Practicable Date; -- 58.1 per cent. to the Volume Weighted Average Price per IDS Share during the one month period ended on the Last Practicable Date; -- 68.2 per cent. to the Volume Weighted Average Price per IDS Share during the three month period ended on the Last Practicable Date; and -- 72.5 per cent. to the Volume Weighted Average Price per IDS Share during the five year period ended on the Last Practicable Date. ..." Read Full Thread Reply
Posted at 18/3/2022 15:51 by sanks SpecialGypo.. My nob is next to the Christmas tree..feel free to stroke it on the way out..thank you. ..or you might want to consider ODX as the skirt is lifted towards £1.10 and above.. Just look at GDR today!!!..ODX share price was hand in hand with GDR recently..so this is an easy £1.10 target!! 30.00 GBX +13.75 (84.62%)today 18 Mar, 16:06 GMT Read Full Thread Reply

Omega Diagnostics share price data is direct from the London Stock Exchange

Omega Diagnostics

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: +44 (0) 203 8794 460 | support@advfn.com

ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil

ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico

ADVFN France ADVFN US ADVFN Korea